ProCE Banner Activity

Refining Therapeutic Approaches in R/R MM: Expert Guidance on Bispecific Antibody Therapy Optimization

Slideset

Enhance your understanding of how bispecific antibodies and combination therapies can be used to treat relapsed/refractory multiple myeloma by reviewing results from key clinical trials and learn how to better manage treatment-related adverse events.

Released: January 17, 2025

Expiration: January 16, 2026

Share

Faculty

Muhamed Baljevic

Muhamed Baljevic, MD, FACP

Associate Professor of Medicine
Director, Plasma Cell Disorders Research
Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP)
Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Caitlin Costello

Caitlin Costello, MD

Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Christopher D'Angelo

Christopher D'Angelo, MD

Assistant Professor
Division of Hematology Oncology
University of Nebraska Medical Center
Omaha, Nebraska

Jens Hillengass

Jens Hillengass, MD, PhD

Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Carol Ann Huff

Carol Ann Huff, MD

Medical Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology and Medicine
Multiple Myeloma Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc